Crossmark

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma

Published Online: 2021-10-08

Published Print: 2022-05

Authors

Cheng, Li https://orcid.org/0000-0002-9479-1768
Creasy, Todd

Pilataxi, Fernanda

Greenlees, Lydia

Vence, Luis

Sridhar, Sriram

Streicher, Katie
License Information

Text and Data Mining valid from 2021-10-08

Version of Record valid from 2021-10-08
More Information

Article History

Received: 1 December 2020

Accepted: 23 September 2021

First Online: 8 October 2021

Declarations

:

: All authors are employees of AstraZeneca and have stock ownership and/or stock options or interests in the company.

: All experiments were conducted in accordance with the ethical standards of the ethics committee of AstraZeneca.

Document is current